Nucleus-targeted Silencer nanoplatform regulating ZEB1-AS1 in head and neck squamous cell carcinoma therapy

Area of Science:

• Oncology
• Molecular Biology
• RNA Therapeutics

Background:

• Long noncoding RNAs (lncRNAs) are implicated in cancer progression.
• ZEB1-AS1 is upregulated in head and neck squamous cell carcinoma (HNSC).
• High ZEB1-AS1 expression correlates with poor prognosis in HNSC patients.

Purpose of the Study:

• Investigate the role of ZEB1-AS1 in HNSC progression, metastasis, and cisplatin resistance.
• Elucidate the molecular mechanism of ZEB1-AS1 action.
• Develop a targeted therapeutic strategy for HNSC.

Main Methods:

• RNA-sequencing analysis to identify candidate lncRNAs.
• In vitro experiments using Cal27 cells to assess ZEB1-AS1 function.
• Nucleus-targeting nanoparticle delivery system for antisense oligonucleotides and siRNA.
• Analysis of ZEB1-AS1, ZEB1, and MOR expression in HNSC datasets.

Main Results:

• Downregulation of ZEB1-AS1 inhibited epithelial-mesenchymal transition and enhanced cisplatin sensitivity.
• Upregulation of ZEB1-AS1 reversed these effects, promoting metastasis and resistance.
• ZEB1-AS1 directly regulates ZEB1 expression, influencing μ opioid receptor (MOR) and cancer progression.
• Nucleus-targeting nanoparticles effectively delivered therapeutic agents in vitro and in vivo.
• A predictive model for HNSC patients was developed based on ZEB1-AS1, ZEB1, and MOR expression.

Conclusions:

• ZEB1-AS1 plays a critical role in HNSC progression, metastasis, and cisplatin resistance.
• Targeting ZEB1-AS1 presents a promising therapeutic avenue for HNSC.
• The nucleus-targeting nanoparticle platform demonstrates potential for efficient ZEB1-AS1-targeted therapy in HNSC.